NEW YORK, Nov. 10, 2015 /PRNewswire/ -- The Global Oncology Partnering 2010-2015 report provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in oncology partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Oncology partnering contract documents
Top oncology deals by value
The Global Oncology Partnering 2010-2015 report provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest oncology agreements announced in the healthcare sector.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all oncology partnering deals announced since 2010 including financial terms where available including over 3,500 links to online deal records of actual oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of the report provide an orientation of oncology dealmaking and its associated business and partnering activities. This chapter provides an overall introduction to the report and what you will learn from it, whilst chapter 2 provides an overview of the trends in oncology deal making since 2010, categorizing by deal type, industry sector, stage of development and technology type.
A popular section with readers; chapter 3 covers the average financial deal terms for deals signed in the oncology field with a stage of development announced. Deals are listed and sectioned by average headlines, upfront payments, milestone payments and royalty rates. The median values of these deals are then presented by stage of development at signing.
Numerous tables and figures are weaved within the report to support the findings and illustrate the trends and activities in oncology partnering and dealmaking since 2010.
Chapter 4 covers the leading oncology deals that have been announced over the past five years. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Full deal contract documents where available for each deal are indicated by a yes/no symbol. Within this chapter the most active oncology deal makers are also listed as well as the deal making activities and the number of deals entered into by the big pharma and biotech companies.
Chapter 5 acts as a contracts reference directory chapter providing a full comprehensive and detailed list of the oncology partnering deals signed and announced since January 2010. This chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy focus. In order for readers to view full details of each agreement the report is formatted so that each deal title links via Weblink to an online version of the actual deal at Current Agreements (www.currentagreements.com) deals and alliances database.
In conclusion, this report gives prospective dealmakers a thorough overview of all the deals announced in the oncology field preparing them with everything they need to know about partnering in the research, development and commercialization of oncology technologies and products.
A full appendix is provided at the very end of the report which lists all the oncology deals announced since 2010 categorized by company A-Z, deal type, stage of development, technology and therapy. Where available contract documents are supplied, these documents include additional deal information in comparison to only the brief summary that is provided through a press release. Readers can analyze the contracts fully by reviewing the detailed terms between the parties under which monies and licensing rights are exchanged. The appendix is useful for looking at all the deals signed by one specific company.
Global Oncology Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to oncology trends and structure of deals entered into by leading companies worldwide.
Global Oncology Partnering 2010-2015 includes:
Trends in oncology dealmaking in the biopharma industry since 2010
Analysis of oncology deal structure
Access to headline, upfront, milestone and royalty data
Access to over 3,500 oncology deal records
The leading oncology deals by value since 2010
In Global Oncology Partnering 2010-2015, the available deals are listed by:
Stage of development at signing
Deal component type
Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Oncology Partnering 2010-2015 report provides comprehensive access to available deals and contract documents for over 3,500 oncology deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?Global Oncology Partnering 2010-2015 provides the reader with the following key benefits:
In-depth understanding of oncology deal trends since 2010
Access to headline, upfront, milestone and royalty data
Comprehensive access to over 3,500 actual oncology deals entered into by the world's biopharma companies
Detailed access to actual oncology contracts enter into by biopharma industries
Insight into the terms included in a oncology agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Read the full report: http://www.reportlinker.com/p03021522-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.